

PERSONAL INFORMATION **Luca Visani, MD**

 Piazza P. Lorenzini, 22 – 50019 – Sesto Fiorentino, Florence, Italy

 +39 3938453655

 luca.visani@unifi.it
visanil@aou-careggi.toscana.it

STUDIES APPLIED FOR **Medical Degree**

WORK EXPERIENCE

Nov 2019–Present Clinical and Radiation Oncology Institute of the Medical School, University of Florence, Azienda Ospedaliero-Universitaria Careggi – Clinical Consultant

Nov 2015–Nov 2019 Clinical and Radiation Oncology Institute of the Medical School, University of Florence, Azienda Ospedaliero-Universitaria Careggi, Florence, Italy - Resident

Jan 2019–Apr 2019 Fellowship for research project at Radiation Oncology Department, Erasmus MC, Rotterdam, The Netherlands

Dec 2014–Oct 2015 Activity as General Practitioner (GP) substitute and territorial medical service

EDUCATION AND TRAINING

16 Nov 2023 Second level University Professional Master's Degree
"Oncological Drugs and Radiotherapy: Biology and Clinics"
University of Brescia, Brescia (Italy)

04 Nov 2019 Specialization in Radiation and Clinical Oncology
70/70 cum laude
University of Florence, Florence (Italy)

25 Mar 2014 Degree in Medicine and Surgery
110/110 cum laude
University of Florence, Florence (Italy)

Jul 2007 High School Degree

PERSONAL SKILLS

Mother tongue Italian

Other languages	UNDERSTANDING		SPEAKING		WRITING
	Listening	Reading	Spoken interaction	Spoken production	
English	C1	C1	C1	C1	C1
French	A2	A2	A2	A2	A2

Communication skills Good communication and team working skills

Digital competence Ability in using the most advanced digital tools and applications

Driving licence B

- 1: Meattini I, Becherini C, Martella F, Del Bene MR, Saieva C, Bacci C, Coltelli L, Pilato G, Visani L, Salvestrini V, Francolini G, Marrazzo L, Bernini M, Orzalesi L, Nori J, Bianchi S, Olivotto I, Morandi A, Curigliano G, Barletta G, Livi L. Cardioprotection in patients with anthracycline-treated breast cancer: final analysis from the 2 × 2 randomized, placebo-controlled, double-blind SAFE trial. *ESMO Open*. 2025 Jun;10(6):105116. doi: 10.1016/j.esmoop.2025.105116. Epub 2025 May 21.
- 2: Scafetta R, Donato M, Gullotta C, Guarino A, Fiore C, Sisca L, Speziale E, Troiano R, Foderaro S, Ricozzi V, Iuliani M, Simonetti S, Cavaliere S, Cortellini A, Botticelli A, Scagnoli S, Pisegna S, Criscitiello C, Pedersini R, Sposetti C, Tiberi E, D'Auria G, Vergati M, Mazzotta M, Caputo R, Verrazzo A, Rossino MG, Domati F, Piombino C, Di Lisa FS, Filomeno L, Arcuri T, Puce F, Riva F, Palleschi M, Sirico M, Piras M, Stucci LS, De Lisi D, Orsaria P, Ippolito E, Ramella S, Visani L, Bertini N, Bonaparte I, Gori S, Rossi L, Meattini I, Tagliaferri B, Caffo O, Portarena I, Irelli A, Cretella E, Porta C, Bianchini G, Fabbri A, De Giorgi U, Vici P, Toss A, Garrone O, De Laurentiis M, Villa F, Berardi R, Minelli M, Vernieri C, Curigliano G, Vincenzi B, Tonini G, Santini D, Pantano F. Comparative analysis of Denosumab and Zoledronic acid in advanced breast cancer patients receiving CDK4/6 inhibitors. *Breast*. 2025 Aug;82:104502. doi: 10.1016/j.breast.2025.104502. Epub 2025 May 15.
- 3: Morelli I, Greto D, Visani L, Lombardi G, Scorsetti M, Clerici E, Navarra P, Minniti G, Livi L, Desideri I. Integrating nutritional status and hematological biomarkers for enhanced prognosis prediction in glioma patients: A systematic review. *Clin Nutr ESPEN*. 2025 Apr;66:269-280. doi: 10.1016/j.clnesp.2025.01.043.
- 4: Meattini I, De Santis MC, Visani L, Scorsetti M, Fozza A, Meduri B, De Rose F, Bonzano E, Prisco A, Masiello V, La Rocca E, Spoto R, Becherini C, Blandino G, Moschetti L, Ray Colciago R, Audisio RA, Brain E, Caini S, Hamaker M, Kaidar-Person O, Lambertini M, Marrazzo M, Saieva C, Spanic T, Strnad S, Wheelwright S, Poortmans PMP, Livi L; EUROPA Trial Investigators. Single-modality endocrine therapy versus radiotherapy after breast-conserving surgery in women aged 70 years and older with luminal A-like early breast cancer (EUROPA): a preplanned interim analysis of a phase 3, non-inferiority, randomised trial. *Lancet Oncol*. 2024 Dec 11:S1470-2045(24)00661-2. doi: 10.1016/S1470-2045(24)00661-2. Online ahead of print.
- 5: Valachis A, Biganzoli L, Christopoulou A, Fjermers K, Fountzila E, Geisler J, Gomez-Bravo R, Karihtala P, Kosmidis P, Koutras A, Linardou H, Lindman H, Martínez-Ballesteros I, Rodríguez AB, Meattini I, Munoz-Mateu M, Othman M, Psyrri A, Risi E, Schiza A, Spathas N, Utriainen M, Visani L, Ballesteros S, Basdekis I, Dieroff Hay S, Fotis T, Fricker S, de Graaf G, Jensen M, Kanter T, Lampropoulos K, Markou C, Mastoraki K, Nanou C, Reales Aviles JM, Santaholma M, Kosmidis T. Implementing geriatric assessment for dose optimization of CDK4/6 inhibitors in older breast cancer patients. *Future Oncol*. 2024;20(37):2937-2948. doi: 10.1080/14796694.2024.2413841. Epub 2024 Oct 21. PMID: 39431459
- 6: Krasniqi E, Filomeno L, Arcuri T, Di Lisa FS, Astone A, Cutigni C, Foglietta J, Nunzi M, Rossi R, Minelli M, Meattini I, Visani L, Scialino J, Livi L, Moschetti L, Marchetti P, Botticelli A, Paris I, Pavese F, D'Angelo T, Sini V, Stani S, Valerio MR, Grassadonia A, Tinari N, Mazzotta M, Vergati M, D'Auria G, Gamucci T, D'Onofrio L, Gasparro S, Roselli A, Fulvi A, Ferretti G, Torchia A, Giordano M, Greco F, Pantano F, Tonini G, Fabbri A, Bria E, Garufi G, Fiorio E, Raffaele M, Pistelli M, Berardi R, Saltarelli R, Kayal R, Ferranti FR, Cannita K, Irelli A, D'Ostilio N, De Rossi C, Palumbo R, Cariello A, Sanguineti G, Calabrò F, Pizzuti L, Barba M, Botti C, Pelle F, Cappelli S, Cavicchi F, Puccica I, Villanucci A, Sperduti I, Ciliberto G, Vici P. Tolerability and Preliminary Outcomes of Adjuvant T-DM1 in HER2-

Positive Breast Cancer After Neoadjuvant Therapy: The ATD Study. *Cancers (Basel)*. 2024 Dec 7;16(23):4104. doi: 10.3390/cancers16234104. PMID: 39682290

- 7: Marrazzo L, Meattini I, Becherini C, Salvestrini V, Visani L, Barletta G, Saieva C, Del Bene MR, Pilato G, Desideri I, Arilli C, Paoletti L, Russo S, Scoccianti S, Martella F, Francolini G, Simontacchi G, Nori Cucchiari J, Pellegrini R, Livi L, Pallotta S. Subclinical cardiac damage monitoring in breast cancer patients treated with an anthracycline-based chemotherapy receiving left-sided breast radiation therapy: subgroup analysis from a phase 3 trial. *Radiol Med*. 2024 Dec;129(12):1926-1935. doi: 10.1007/s11547-024-01897-6. Epub 2024 Oct 22. PMID: 39436588
- 8: Salvestrini V, Valzano M, Meattini I, Becherini C, Visani L, Francolini G, Morelli I, Bertini N, Orzalesi L, Bernini M, Bianchi S, Simontacchi G, Livi L, Desideri I. Anatomical assessment of local recurrence site in breast cancer patients after breast reconstruction and post-mastectomy radiotherapy: implications for radiation volumes and techniques. *Radiol Med*. 2024 Jun;129(6):845-854. doi: 10.1007/s11547-024-01812-z. Epub 2024 Apr 11. PMID: 38602657
- 9: Bernini M, Gigliucci G, Cassetti D, Tommasi C, Gaggelli I, Arlia L, Becherini C, Salvestrini V, Visani L, Nori Cucchiari J, De Benedetto D, Di Naro F, Bicchierai G, Bellini C, Bianchi S, Orzalesi L, Livi L, Meattini I. Pre-pectoral breast reconstruction with tissue expander entirely covered by acellular dermal matrix: feasibility, safety and histological features resulting from the first 64 procedures. *Gland Surg*. 2024 Mar 27;13(3):297-306. doi: 10.21037/gs-23-432. Epub 2024 Mar 22. PMID: 38601291
- 10: Becherini C, Salvestrini V, Desideri I, Vagnoni G, Bonaparte I, Bertini N, Mattioli C, Angelini L, Visani L, Scotti V, Livi L, Caini S, Bonomo P. Impact of fosaprepitant in the prevention of nausea and emesis in head and neck cancer patients undergoing cisplatin-based chemoradiation: a pilot prospective study and a review of literature. *Radiol Med*. 2024 Mar;129(3):457-466. doi: 10.1007/s11547-024-01757-3. Epub 2024 Feb 14. PMID: 38351333
- 11: Zampieri M, Schoonvelde SAC, Vinci M, Meattini I, Visani L, Fornaro A, Coppini R, Romei A, Marchi A, Morelli I, van Slegtenhorst MA, Palinkas ED, Livi L, Michels M, Olivotto I. Cancer Treatment-Related Complications in Patients With Hypertrophic Cardiomyopathy. *Mayo Clin Proc*. 2024 Feb;99(2):218-228. doi: 10.1016/j.mayocp.2023.10.003. Epub 2024 Jan 5. PMID: 38180395
- 12: Meattini I, Becherini C, Caini S, Coles CE, Cortes J, Curigliano G, de Azambuja E, Isacke CM, Harbeck N, Kaidar-Person O, Marangoni E, Offersen BV, Rugo HS, Salvestrini V, Visani L, Morandi A, Lambertini M, Poortmans P, Livi L; Consensus Panellist Group. International multidisciplinary consensus on the integration of radiotherapy with new systemic treatments for breast cancer: European Society for Radiotherapy and Oncology (ESTRO)-endorsed recommendations. *Lancet Oncol*. 2024 Feb;25(2):e73-e83. doi: 10.1016/S1470-2045(23)00534-X. PMID: 38301705
- 13: Desideri I, Morelli I, Banini M, Greto D, Visani L, Nozzoli F, Caini S, Della Puppa A, Livi L, Perini Z, Zivelonghi E, Bulgarelli G, Pinzi V, Navarria P, Clerici E, Scorsetti M, Ascolese AM, Osti MF, Anselmo P, Amelio D, Minniti G, Scartoni D. Re-irradiation for recurrent intracranial meningiomas: Analysis of clinical outcomes and prognostic factors. *Radiother Oncol*. 2024 Jun;195:110271. doi: 10.1016/j.radonc.2024.110271. Epub 2024 Apr 7. PMID: 38588920
- 14: Desideri I, Morelli I, Banini M, Greto D, Visani L, Nozzoli F, Caini S, Della Puppa A, Livi L, Perini Z, Zivelonghi E, Bulgarelli G, Pinzi V, Navarria P, Clerici E, Scorsetti M, Ascolese AM, Osti MF, Anselmo P, Amelio D, Minniti G, Scartoni D. Response to Tugcu et al. *Radiother Oncol*. 2024 Jun 8:110378. doi: 10.1016/j.radonc.2024.110378. Online ahead of print. PMID: 38857703
- 15: Becherini C, Visani L, Caini S, Bhattacharya IS, Kirby AM, Nader Marta G, Morgan G, Salvestrini V, Coles CE, Cortes J, Curigliano G, de Azambuja E, Harbeck N, Isacke CM, Kaidar-Person O, Marangoni E, Offersen B, Rugo HS, Morandi A, Lambertini M, Poortmans P, Livi L, Meattini I. Safety profile of cyclin-dependent kinase (CDK) 4/6 inhibitors with concurrent radiation therapy: A systematic

review and meta-analysis. *Cancer Treat Rev.* 2023 Sep;119:102586. doi:10.1016/j.ctrv.2023.102586. Epub 2023 Jun 15. PMID: 37336117.

- 16: Salvestrini V, Kim K, Caini S, Alkner S, Ekholm M, Skyttä T, Becherini C, Coles CE, Kaidar-Person O, Offersen B, de Azambuja E, Visani L, Cortes J, Harbeck N, Rugo HS, Isacke CM, Marangoni E, Morandi A, Lambertini M, Poortmans P, Livi L, Meattini I. Safety profile of trastuzumab-emtansine (T-DM1) with concurrent radiation therapy: A systematic review and meta-analysis. *Radiother Oncol.* 2023 Sep;186:109805. doi: 10.1016/j.radonc.2023.109805. Epub 2023 Jul 10. PMID: 37437610.
- 17: Criscitiello C, Corti C, De Laurentiis M, Bianchini G, Pistilli B, Cinieri S, Castellan L, Arpino G, Conte P, Di Meco F, Gennari A, Guarneri V, Visani L, Livi L, Marchetti P, Puglisi F, Viale G, Del Mastro L, De Placido S, Curigliano G. Tucatinib's journey from clinical development to clinical practice: New horizons for HER2-positive metastatic disease and promising prospects for brain metastatic spread. *Cancer Treat Rev.* 2023 Nov;120:102618. doi:10.1016/j.ctrv.2023.102618. Epub 2023 Aug 22. PMID: 37639757.
- 18: Marano L, Marmorino F, Desideri I, Carbone L, Rizzo A, Salvestrini V, Roviello F, Cinieri S, Donato V, De Luca R; NutriOnc Research Group. Clinical nutrition in surgical oncology: Young AIOM-AIRO-SICO multidisciplinary national survey on behalf of NutriOnc research group. *Front Nutr.* 2023 Apr 14;10:1045022. doi: 10.3389/fnut.2023.1045022. PMID: 37125048; PMCID: PMC10140427.
- 19: Lambertini M, Blondeaux E, Agostinetti E, Hamy AS, Kim HJ, Di Meglio A, Bernstein Molho R, Hilbers F, Pogoda K, Carrasco E, Punie K, Bajpai J, Ignatiadis M, Moore HCF, Phillips KA, Toss A, Rousset-Jablonski C, Peccatori FA, Renaud T, Ferrari A, Paluch-Shimon S, Fruscio R, Cui W, Wong SM, Vernieri C, Ruddy KJ, Dieci MV, Matikas A, Rozenblit M, Villarreal-Garza C, De Marchis L, Del Mastro L, Puglisi F, Del Pilar Estevez-Diz M, Rodriguez-Wallberg KA, Mrinakova B, Meister S, Livraghi L, Clatot F, Yerushalmi R, De Angelis C, Sánchez-Bayona R, Meattini I, Cichowska-Cwalinska N, Berlière M, Salama M, De Giorgi U, Sonnenblick A, Chiodi C, Lee YJ, Maria C, Azim HA Jr, Boni L, Partridge AH; BRCA BCY Collaboration. Pregnancy After Breast Cancer in Young BRCA Carriers: An International Hospital-Based Cohort Study. *JAMA.* 2024 Jan 2;331(1):49-59. doi: 10.1001/jama.2023.25463. PMID: 38059899; PMCID: PMC10704340.
- 20: Banini M, Visani L, Livi L, Meattini I. De-escalating postoperative radiation therapy after primary systemic therapy in cT1-2N1 breast cancer: lesson from the RAPCHEM/BOOG 2010-03 trial. *Ann Transl Med.* 2023 Aug 30;11(10):366. doi:10.21037/atm-23-1051. Epub 2023 Apr 11. PMID: 37675297; PMCID: PMC10477657.
- 21: Francolini G, Ghoshal A, Caini S, Piazzini T, Becherini C, Detti B, Di Cataldo V, Valzano M, Visani L, Salvestrini V, Olmetto E, Desideri I, Meattini I, Livi L. Quality of life after definitive treatment for bladder cancer: A systematic review and meta-analysis. *Radiother Oncol.* 2023 Nov 30;190:110038. doi: 10.1016/j.radonc.2023.110038. Epub ahead of print. PMID: 38042498.
- 22: Meattini I, Livi L, Lorito N, Becherini C, Bacci M, Visani L, Fozza A, Belgioia L, Loi M, Mangoni M, Lambertini M, Morandi A. Integrating radiation therapy with targeted treatments for breast cancer: From bench to bedside. *Cancer Treat Rev.* 2022 Jul;108:102417. doi: 10.1016/j.ctrv.2022.102417. Epub 2022 May 21. PMID: 35623219.
- 23: Miglietta F, Visani L, Marini S, Griguolo G, Vernaci GM, Bottosso M, Dieci MV, Meattini I, Guarneri V. Oligometastatic breast cancer: Dissecting the clinical and biological uniqueness of this emerging entity. Can we pursue curability? *Cancer Treat Rev.* 2022 Nov;110:102462. doi:10.1016/j.ctrv.2022.102462. Epub 2022 Sep 6. PMID: 36087503.
- 24: Kaidar-Person O, Meattini I, Boersma LJ, Becherini C, Cortes J, Curigliano G, de Azambuja E, Harbeck N, Rugo HS, Del Mastro L, Gennari A, Isacke CM, Vestmø Maraldo M, Marangoni E, Nader Marta G, Mjaaland I, Salvestrini V, Spanic T, Visani L, Morandi A, Lambertini M, Livi L, Coles CE, Poortmans P, Offersen BV. Essential requirements for reporting radiation therapy in breast cancer

clinical trials: an international multi-disciplinary consensus endorsed by the European Society for Radiotherapy and Oncology (ESTRO). *Radiother Oncol.* 2023 Dec 18;110060. doi: 10.1016/j.radonc.2023.110060. Epub ahead of print. PMID:38122852.

- 25: Masi L, Doro R, Di Cataldo V, Francolini G, Zani M, Visani L, Meattini I, Livi L. Preoperative single fraction breast radiotherapy: Intra-fraction geometric uncertainties and dosimetric implications. *Phys Med.* 2023 Aug;112:102638. doi: 10.1016/j.ejmp.2023.102638. Epub 2023 Jul 11. PMID:37441821.
- 26: Francolini G, Ganovelli M, Di Cataldo V, Detti B, Caini S, Loi M, Simontacchi G, Desideri I, Greto D, Valzano M, Serni S, Vaggelli L, Salvestrini V, Visani L, Becherini C, Olmetto E, Franzese C, Baldaccini D, Scorsetti M, Sollini M, Chiti A, Meattini I, Valicenti RK, Livi L. Early biochemical outcomes following PSMA guided approach for biochemical relapse after prostatectomy-PSICHE trial (NCT05022914): preliminary results. *Clin Exp Metastasis.* 2023 Apr;40(2):197-201. doi: 10.1007/s10585-023-10204-y. Epub 2023 Apr 3. PMID: 37012498; PMCID:PMC10113311.
- 27: Trovò M, Franceschini D, Furlan C, Pietrobon F, Vagge S, Farina E, Revelant A, Visani L, Maragna V, Parisi G, Scotti V. Extra-pleural pneumonectomy in the era of image-guided intensity-modulated radiotherapy. *Radiol Med.* 2019 Sep;124(9):854-859. doi: 10.1007/s11547-019-01030-y. Epub 2019 Apr 8. PMID:30963379.
- 28: Aquilano M, Loi M, Visani L, Livi L, Nuytens JJ. Is stereotactic body radiotherapy an effective treatment in metastatic lung cancer with oligoprogressive disease? *Acta Oncol.* 2023 Mar;62(3):298-304. doi:10.1080/0284186X.2023.2186187. Epub 2023 Mar 11. PMID: 36905644.
- 29: Pasqualetti F, Montemurro N, Desideri I, Loi M, Giannini N, Gadducci G, Malfatti G, Cantarella M, Gonnelli A, Montrone S, Visani L, Scatena C, Naccarato AG, Perrini P, Gambacciani C, Santonocito O, Morganti R, Paiar F. Impact of recurrence pattern in patients undergoing a second surgery for recurrent glioblastoma. *Acta Neurol Belg.* 2022 Apr;122(2):441-446. doi:10.1007/s13760-021-01765-4. Epub 2021 Aug 16. PMID: 34396487.
- 30: Francolini G, Carnevale MG, Di Cataldo V, Loi M, Detti B, Orsatti C, Caprara L, Bertini N, Lorenzetti V, Olmetto E, Becherini C, Visani L, Salvestrini V, Simontacchi G, Greto D, Bonomo P, Doro R, Masi L, Desideri I, Meattini I, Serni S, Livi L. Stereotactic reirradiation with Cyberknife for locally recurrent prostate cancer, long-term toxicity and clinical outcomes from a monocentric cohort. *Radiol Med.* 2023 Dec;128(12):1580-1588. doi: 10.1007/s11547-023-01721-7. Epub 2023 Sep 20. PMID: 37728816.
- 31: Desideri I, Becherini C, Visani L, Stocchi G, Scoccimarro E, Mariotti M, Salvestrini V, Scoccianti S, Greto D, Bonomo P, Pecchioli G, Bordini L, Della Puppa A, Francolini G, Meattini I, Livi L. Outcome and prognostic factors for older patients undergoing radiosurgery for brain metastases. *J Geriatr Oncol.* 2020 Sep;11(7):1103-1107. doi: 10.1016/j.jgo.2020.03.009. Epub 2020 Apr 4. PMID: 32253160.
- 32: Francolini G, Desideri I, Detti B, Di Cataldo V, Masi L, Caramia G, Visani L, Terziani F, Muntoni C, Lo Russo M, Loi M, Livi L. Stereotactic radiotherapy in oligoprogressive and oligorecurrent urothelial cancer patients: A retrospective experience. *Cancer Treat Res Commun.* 2019;19:100124. doi: 10.1016/j.ctarc.2019.100124. Epub 2019 Feb 19. PMID: 30851645.
- 33: Francolini G, Garlatti P, Di Cataldo V, Detti B, Loi M, Greto D, Simontacchi G, Morelli I, Burchini L, Allegra AG, Frosini G, Ganovelli M, Salvestrini V, Olmetto E, Visani L, Becherini C, Valzano M, Carnevale MG, Roghi M, Serni S, Mattioli C, Desideri I, Livi L. Three Months' PSA and Toxicity from a Prospective Trial Investigating STereotactic sAlvage Radiotherapy for Macroscopic Prostate Bed Recurrence after Prostatectomy-STARR (NCT05455736). *Cancers (Basel).* 2023 Feb 3;15(3):992. doi: 10.3390/cancers15030992. PMID: 36765948; PMCID: PMC9913280.
- 34: Meattini I, Francolini G, Di Cataldo V, Visani L, Becherini C, Scoccimarro E, Salvestrini V, Bellini C, Masi L, Doro R, Di Naro F, Loi M, Salvatore G, Simontacchi G, Greto D, Bernini M, Nori J, Orzalesi L, Bianchi S, Mangoni M, Livi L. Preoperative robotic radiosurgery for early breast cancer: Results of the

phase II ROCK trial (NCT03520894). *Clin Transl Radiat Oncol*. 2022 Sep 22;37:94-100. doi: 10.1016/j.ctro.2022.09.004. PMID: 36177053; PMCID: PMC9513617.

- 35: Visani L, Livi L, Ratosi I, Orazem M, Ribnikar D, Saieva C, Becherini C, Salvestrini V, Scoccimarro E, Valzano M, Cerbai C, Desideri I, Bernini M, Orzalesi L, Nori J, Bianchi S, Morandi A, Meattini I. Safety of CDK4/6 inhibitors and concomitant radiation therapy in patients affected by metastatic breast cancer. *Radiother Oncol*. 2022 Dec;177:40-45. doi: 10.1016/j.radonc.2022.10.023. Epub 2022 Oct 28. PMID: 36349599.
- 36: Greto D, Saieva C, Loi M, Terziani F, Visani L, Garlatti P, Lo Russo M, Muntoni C, Becherini C, Topulli J, Campanacci D, Beltrami G, Scoccianti G, Muratori F, Bonomo P, Desideri I, Francolini G, Livi L. Influence of age and subtype in outcome of operable liposarcoma. *Radiol Med*. 2019 Apr;124(4):290-300. doi: 10.1007/s11547-018-0958-4. Epub 2018 Nov 12. PMID: 30421387.
- 37: Francolini G, Banini M, Di Cataldo V, Detti B, Caini S, Loi M, Simontacchi G, Desideri I, Greto D, Valzano M, Roghi M, Serni S, Vaggelli L, Salvestrini V, Visani L, Becherini C, Olmetto E, Franzese C, Baldaccini D, Scorsetti M, Sollini M, Chiti A, Meattini I, Valicenti RK, Livi L. PSMA guided approach for biochemical relapse after prostatectomy- (PSICHE) trial (NCT05022914). Detection rate and treatment decision after 68Ga-PSMA PET/CT within a prospective study. *Prostate*. 2023 Sep;83(12):1201-1206. doi: 10.1002/pros.24579. Epub 2023 Jun 8. PMID: 37290915.
- 38: Francolini G, Frosini G, Di Cataldo V, Detti B, Carnevale MG, Banini M, Peruzzi A, Salvestrini V, Visani L, Olmetto E, Becherini C, Allegra A, Burchini L, Scotti V, Mangoni M, Meattini I, Desideri I, Livi L. Predictive factors for tolerance to taxane based chemotherapy in older adults affected by metastatic prostate cancer (ANCHISES-NCT05471427): A prospective observational trial including patients with metastatic hormone sensitive and castrate resistant prostate cancer treated with taxane chemotherapy. *J Geriatr Oncol*. 2023 Jan;14(1):101411. doi: 10.1016/j.jgo.2022.11.010. Epub 2022 Dec 8. PMID: 36496347.
- 39: Greto D, Saieva C, Loi M, Desideri I, Delli Paoli C, Lo Russo M, Pezzulla D, Teriaca MA, Lucidi S, Visani L, Terziani F, Olmetto E, Becherini C, Bonomo P, Francolini G, Campanacci DA, Scoccianti G, Livi L. Patterns of Care and Survival in Elderly Patients With Locally Advanced Soft Tissue Sarcoma. *Am J Clin Oncol*. 2019 Oct;42(10):749-754. doi: 10.1097/COC.0000000000000594. PMID: 31503061.
- 40: Greto D, Loi M, Terziani F, Visani L, Garlatti P, Lo Russo M, Teriaca A, Muntoni C, Delli Paoli C, Topulli J, Campanacci D, Beltrami G, Scoccianti G, Bonomo P, Desideri I, Francolini G, Livi L. A matched cohort study of radio-chemotherapy versus radiotherapy alone in soft tissue sarcoma patients. *Radiol Med*. 2019 Apr;124(4):301-308. doi: 10.1007/s11547-018-0939-7. Epub 2018 Sep 12. PMID: 30209796.
- 41: Francolini G, Campi R, Di Cataldo V, Detti B, Loi M, Triggiani L, La Mattina S, Borghetti P, Magrini SM, Nicosia L, Alongi F, Ghirardelli P, Vavassori V, Allegra AG, Aquilano M, Scoccimarro E, Peruzzi A, Pastina P, Visani L, Desideri I, Serni S, Meattini I, Livi L. Impact of stereotactic body radiotherapy vs palliative radiotherapy on oncologic outcomes of patients with metastatic kidney cancer concomitantly treated with immune checkpoint inhibitors: a preliminary, multicentre experience. *Clin Transl Oncol*. 2022 Oct;24(10):2039-2043. doi: 10.1007/s12094-022-02844-5. Epub 2022 Jun 23. PMID: 35739349; PMCID: PMC9418086.
- 42: Francolini G, Detti B, Di Cataldo V, Garlatti P, Aquilano M, Allegra A, Lucidi S, Cerbai C, Ciccone LP, Salvestrini V, Stocchi G, Guerrieri B, Visani L, Loi M, Desideri I, Mangoni M, Meattini I, Livi L. Study protocol and preliminary results from a mono-centric cohort within a trial testing stereotactic body radiotherapy and abiraterone (ARTO-NCT03449719). *Radiol Med*. 2022 Aug;127(8):912-918. doi: 10.1007/s11547-022-01511-7. Epub 2022 Jun 28. PMID: 35763249; PMCID: PMC9349091.
- 43: Livi L, Barletta G, Martella F, Saieva C, Desideri I, Bacci C, Del Bene MR, Airolidi M, Amoroso D, Coltelli L, Scotti V, Becherini C, Visani L, Salvestrini V, Mariotti M, Pedani F, Bernini M, Sanchez L,

- Orzalesi L, Nori J, Bianchi S, Olivotto I, Meattini I. Cardioprotective Strategy for Patients With Nonmetastatic Breast Cancer Who Are Receiving an Anthracycline-Based Chemotherapy: A Randomized Clinical Trial. *JAMA Oncol.* 2021 Oct 1;7(10):1544-1549. doi: 10.1001/jamaoncol.2021.3395. PMID: 34436523; PMCID: PMC8391772.
- 44: Meattini I, Poortmans P, Kirova Y, Saieva C, Visani L, Salvestrini V, Kim J, Jung W, Olmetto E, Mariotti M, Desideri I, Fourquet A, Livi L, Kim K. Hypofractionated whole breast irradiation after conservative surgery for patients aged less than 60 years: a multi-centre comparative study. *Acta Oncol.* 2020 Feb;59(2):188-195. doi: 10.1080/0284186X.2019.1695061. Epub 2019 Nov 25. PMID: 31760849.
- 45: Desideri I, Lucidi S, Francolini G, Meattini I, Ciccone LP, Salvestrini V, Valzano M, Morelli I, Angelini L, Scotti V, Bonomo P, Greto D, Terziani F, Becherini C, Visani L, Livi L. Use of an alfa-lipoic, Methylsulfonylmethane, Boswellia serrata and Bromelain dietary supplement (OPERA®) for aromatase inhibitors-related arthralgia management (AIA): a prospective phase II trial (NCT04161833). *Med Oncol.* 2022 Jun 6;39(8):113. doi: 10.1007/s12032-022-01723-x. PMID: 35666314.
- 46: Bernini M, Meattini I, Saieva C, Becherini C, Salvestrini V, Visani L, Stocchi G, Bellini C, Lorenzetti V, Sordi S, Nori J, De Benedetto D, Desideri I, Bianchi S, Livi L, Orzalesi L. Pre-pectoral breast reconstruction: early and long-term safety evaluation of 146 unselected cases of the early pre-pectoral era of a single-institution, including cases with previous breast irradiation and post-mastectomy radiation therapy. *Breast Cancer.* 2022 Mar;29(2):302-313. doi: 10.1007/s12282-021-01314-0. Epub 2021 Nov 14. PMID: 34775540.
- 47: Meattini I, Poortmans PMP, Marrazzo L, Desideri I, Brain E, Hamaker M, Lambertini M, Miccinesi G, Russell N, Saieva C, Strnad V, Visani L, Kaidar-Person O, Livi L. Exclusive endocrine therapy or partial breast irradiation for women aged ≥ 70 years with luminal A-like early stage breast cancer (NCT04134598- EUROPA): Proof of concept of a randomized controlled trial comparing health related quality of life by patient reported outcome measures. *J Geriatr Oncol.* 2021 Mar;12(2):182-189. doi: 10.1016/j.jgo.2020.07.013. Epub 2020 Jul 29. PMID: 32739355.
- 48: Francolini G, Loi M, Ciccone LP, Detti B, Di Cataldo V, Pinzani P, Salvianti F, Salvatore G, Sottili M, Santini C, Frosini G, Visani L, Burchini L, Mattioli C, Allegra AG, Valzano M, Cerbai C, Aquilano M, Salvestrini V, Desideri I, Mangoni M, Meattini I, Livi L. Prospective assessment of AR splice variant and multi-biomarker expression on circulating tumor cells of mCRPC patients undergoing androgen receptor targeted agents: interim analysis of PRIMERA trial (NCT04188275). *Med Oncol.* 2022 Jun 10;39(8):119. doi: 10.1007/s12032-022-01756-2. PMID: 35687207.
- 49: Desideri I, Francolini G, Carta GA, Di Cataldo V, Masi L, Meattini I, Bonomo P, Loi M, Greto D, Visani L, Lo Russo M, Grassi R, Teriaca MA, Garlatti P, Nardi C, Livi L. Efficacy and Tolerability of CyberKnife Stereotactic Robotic Radiotherapy for Primary or Secondary Orbital Lesions: A Single-Center Retrospective Experience. *Technol Cancer Res Treat.* 2019 Jan 1;18:1533033818818561. doi: 10.1177/1533033818818561. PMID: 30803353; PMCID: PMC6373998.
- 50: Desideri I, Francolini G, Scotti V, Pezzulla D, Becherini C, Terziani F, Delli Paoli C, Olmetto E, Visani L, Meattini I, Greto D, Bonomo P, Loi M, Detti B, Livi L. Benefit of ablative versus palliative-only radiotherapy in combination with nivolumab in patients affected by metastatic kidney and lung cancer. *Clin Transl Oncol.* 2019 Jul;21(7):933-938. doi: 10.1007/s12094-018-02005-7. Epub 2018 Dec 18. PMID: 30565084.
- 51: Borghetti P, Bonù ML, Giubolini R, Levra NG, Mazzola R, Perna M, Visani L, Meacci F, Taraborrelli M, Triggiani L, Franceschini D, Greco C, Bruni A, Magrini SM, Scotti V. Concomitant radiotherapy and TKI in metastatic EGFR- or ALK-mutated non-small cell lung cancer: a multicentric analysis on behalf of AIRO lung cancer study group. *Radiol Med.* 2019 Jul;124(7):662-670. doi: 10.1007/s11547-019-00999-w. Epub 2019 Feb 15. PMID: 30771218.

- 52: Bonomo P, Greto D, Desideri I, Loi M, Di Cataldo V, Orlandi E, Iacovelli NA, Becherini C, Visani L, Salvestrini V, Mariotti M, Livi L. Clinical outcome of stereotactic body radiotherapy for lung-only oligometastatic head and neck squamous cell carcinoma: Is the deferral of systemic therapy a potential goal? *Oral Oncol.* 2019 Jun;93:1-7. doi: 10.1016/j.oraloncology.2019.04.006. Epub 2019 Apr 8. PMID: 31109688.
- 53: Livi L, Scotti V, Desideri I, Saieva C, Cecchini S, Francolini G, Becherini C, Delli Paoli C, Visani L, Salvestrini V, De Feo ML, Nori J, Bernini M, Sanchez L, Orzalesi L, Bianchi S, Meattini I. Phase 2 placebo-controlled, single-blind trial to evaluate the impact of oral ibandronate on bone mineral density in osteopenic breast cancer patients receiving adjuvant aromatase inhibitors: 5-year results of the single-centre BONADIUV trial. *Eur J Cancer.* 2019 Feb;108:100-110. doi: 10.1016/j.ejca.2018.12.005. Epub 2019 Jan 14. PMID: 30648627.
- 54: Scoccianti S, Francolini G, Carta GA, Greto D, Detti B, Simontacchi G, Visani L, Baki M, Poggesi L, Bonomo P, Mangoni M, Desideri I, Pallotta S, Livi L. Re-irradiation as salvage treatment in recurrent glioblastoma: A comprehensive literature review to provide practical answers to frequently asked questions. *Crit Rev Oncol Hematol.* 2018 Jun;126:80-91. doi:0.1016/j.critrevonc.2018.03.024. Epub 2018 Mar 31. PMID: 29759570.

INTERNATIONAL MEMBERSHIPS

- Member of EORTC Breast Cancer Group (BCG)
- Member of EORTC Brain Tumor Group (BTG)
- Member of European Society for Radiotherapy and Oncology (ESTRO)
- Member of European Society of Medical Oncology (ESMO)

COURSES AND CONGRESSES

- Speaker at AIRO (Italian Radiation Oncology Society) National Congress 2024 - Milan, Italy (21-23 Jun 2024)
- Invited member at EORTC BCG retreat meeting – Bordeaux, France (29-30 Sep 2023)
- Speaker at ESTRO (European Society for Radiotherapy and Oncology) 2022 Congress – Copenhagen, Denmark (6-10 May 2022)
- Speaker at ESTRO (European Society for Radiotherapy and Oncology) 2021 Congress – Madrid, Spain (27-31 August 2021)
- Attendance to EORTC Soft Tissue and Bone Sarcoma Group (STBSG) biannual meeting – Madrid, Spain (17-18 Oct 2019)
- Speaker at AIRO (Italian Radiation Oncology Society) National Congress 2019 – Rimini, Italy (27-29 Sep 2019)
- Attendance to EORTC Radiation Oncology Group (ROG) biannual meeting – Lyon, France (23-24 Sep 2019)
- Attendance to EORTC Breast Cancer Group (BCG) biannual meeting – Leuven, Belgium (13-14 Sep 2019)
- Attendance to EORTC course “Clinical Trials Statistics for Non-Statisticians” – Bruxelles, Belgium (12-14 Jun 2019)
- Attendance to EORTC Radiation Oncology Group (ROG) biannual meeting – Rotterdam, The Netherlands (1-2 Oct 2018)
- Speaker at AIRO (Italian Radiation Oncology Society) National Congress 2018 – Rimini, Italy (2-4 Nov 2018)

- Speaker at AIRO (Italian Radiation Oncology Society) National Congress 2017 – Rimini, Italy (11-13 Nov 2017)
- Speaker at SIET (Italian Thoracic Endoscopy Society) National Congress 2017 – Lecce, Italy (28-30 Nov 2017)

EXPERIENCE IN CLINICAL TRIALS

Experience as study sub-investigator in many profit and no-profit clinical trials.

Lettera programmatica – Candidatura a Consigliere del Gruppo di Studio Mammella AIRO

Cari Colleghi, Care Colleghe,

con grande piacere desidero sottoporre la mia candidatura per il ruolo di Consigliere del Gruppo di Studio Mammella dell'Associazione Italiana di Radioterapia e Oncologia Clinica per il prossimo biennio 2026-2027.

Svolgo da alcuni anni la mia attività presso l'Azienda Ospedaliero-Universitaria Careggi di Firenze, dove ho conseguito la specializzazione in Radioterapia nel 2019. Fin dal periodo di formazione, ho sviluppato un interesse specifico per la ricerca clinica spontanea, partecipando inoltre attivamente come sub-investigatore a studi nazionali ed internazionali dedicati in particolare alla patologia mammaria.

Nel corso degli anni ho acquisito esperienza nella gestione di tutte le fasi del trattamento radioterapico della mammella, oltre che nell'utilizzo di protocolli di terapia sistemica, con particolare attenzione alla loro integrazione con i trattamenti locoregionali. Ho inoltre contribuito a progetti di miglioramento della qualità e di ottimizzazione dei percorsi terapeutici, con un impegno costante nella promozione della gestione multidisciplinare delle pazienti con carcinoma mammario.

Ritengo che la mia esperienza clinica, unita all'interesse per l'innovazione e alla propensione al lavoro di squadra, possano apportare un contributo al Gruppo di Studio.

Con entusiasmo sono pronto a mettere a disposizione le mie competenze e la mia energia per collaborare al raggiungimento degli obiettivi comuni e allo sviluppo delle attività del Gruppo.

Cordiali saluti e a presto,

Dr. Luca Visani
Dirigente Medico
SOD Radioterapia – AOU Careggi, Firenze

luca.visani@unifi.it